Civica Rx

Civica Rx
Industry	Generic drug development
Founded	September 6, 2018
Headquarters	Lehi, Utah
Key people	Martin VanTrieste; (President and CEO)
Website	www.civicarx.org

Civica Rx is a nonprofit generic drug manufacturer founded in 2018 in response to shortages and high pricing of urgently needed generic medications in the United States.[1]

Civica Rx was started by national philanthropies and leading US health systems. [2] By the end of 2019, over 45 health systems representing 1200 hospitals were members of Civica. Member hospital pharmacists and clinicians help prioritize the medications Civica makes. The company's initial business plan was to produce 14 generic drugs for hospitals in 2019. By the end of 2019 Civica had 18 medications (28 SKUs) in production, and plans to bring over 100 medications to market in five years through various manufacturing approaches such as partnerships, developing ANDAs, and building its own manufacturing capability.

The first shipment of Civica private-label medication was vancomycin, delivered to Riverton Hospital, a part of Civica founder health system Intermountain Healthcare, in October 2019.[3]

Partnerships and deals

In January of 2020, Civica Rx announced a seven-year partnership with Thermo Fisher to produce nine drugs for emergency and critical care applications that are vulnerable to frequent shortages.[3] This is the first deal in which a manufacturer would produce drugs under an ANDA owned by Civica Rx itself, rather than under the manufacturer's ANDA.

In July 2019, it announced a supplier partnership with Hikma Pharmaceuticals to provide 14 essential medicines used daily by hospitals in emergency care, surgery, pain management and hypertension treatment. [4]. By the end of 2019 Civica was working with five confirmed supplier partners and in negotiations with several more.

In May 2019, Civica announced that Xellia Pharmaceuticals of Copenhagen, Denmark, was its first supplier partnership and would provide the antibiotics vancomycin and daptomycin[5].

gollark: ++delete trigraphs

gollark: goto is NOT part of a balanced diet.

gollark: GOTO considered harmful.

gollark: `locale.h` and `iso646.h` will be removed and everyone will be forced to speak C.

gollark: `threads.h` will be removed since I read somewhere that you should just be using multiple processes anyway.

References

Kodjak, Alison (6 September 2018). "Hospitals Prepare To Launch Their Own Drug Company To Fight High Prices And Shortages". NPR. Retrieved 6 September 2018.
Johnson, Carolyn (6 September 2018). "Hospitals are fed up with drug companies, so they're starting their own". Washington Post.
Gardner, Jonathan (January 16, 2020). "Civica advances drug supply strategy with Thermo Fisher deal". Biopharma Drive.
"Hikma and Civica Rx sign long-term agreement to reduce generic drug shortages in the US". PR Newswire. Cision. July 23, 2019.
Garguilo, Louis. "Ending Generic Drug Shortages At Hospitals: A Capitalist Goes Nonprofit". Life Science Leader (July, 2019). Retrieved 14 August 2019.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Kodjak, Alison (6 September 2018). "Hospitals Prepare To Launch Their Own Drug Company To Fight High Prices And Shortages". NPR. Retrieved 6 September 2018.

[WP2018-2] Johnson, Carolyn (6 September 2018). "Hospitals are fed up with drug companies, so they're starting their own". Washington Post.

[Gardner2020-3] Gardner, Jonathan (January 16, 2020). "Civica advances drug supply strategy with Thermo Fisher deal". Biopharma Drive.

[Hikma2019-4] "Hikma and Civica Rx sign long-term agreement to reduce generic drug shortages in the US". PR Newswire. Cision. July 23, 2019.

[5] Garguilo, Louis. "Ending Generic Drug Shortages At Hospitals: A Capitalist Goes Nonprofit". Life Science Leader (July, 2019). Retrieved 14 August 2019.